Trade Names:Totect- Injection, lyophilized powder for solution 500 mg
Trade Names:Zinecard- Injection, lyophilized powder for solution 250 mg (10 mg/mL reconstituted)- Injection, lyophilized powder for solution 500 mg (10 mg/mL reconstituted)
Dexrazoxane is a potent intracellular chelating agent. The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood.
C max is 36.5 mcg/mL (at end of infusion).
Vd approximately 22 L/m 2 . Not bound to plasma proteins.
Metabolized to a diacid-diamide cleavage product and 2 monoacid-monoamide ring products.
Elimination t ½ is 2.1 to 2.5 h. Plasma Cl is 6.25 to 7.88 L/h/m 2 . Renal Cl is 3.35 L/h/m 2 ; 42% excreted in urine.
Cl is reduced in patients with renal function impairment.Hepatic Function Impairment
Pharmacokinetics have not been evaluated.Elderly
No pharmacokinetic differences have been observed in patients 65 yr of age and older with healthy renal function compared with younger patients.Children
Pharmacokinetics have not been evaluated.Gender
Pharmacokinetics not affected by gender.
Treatment of extravasation resulting from IV anthracycline chemotherapy.Zinecard
Reduce incidence and severity of cardiomyopathy in women with breast cancer patients who have received a cumulative doxorubicin dose of 300 mg/m 2 and who may benefit from additional doxorubicin therapy. It is not recommended for use with the initiation of doxorubicin therapy.
Cardioprotectant for other anthracyclines.
Do not use with chemotherapy regimens that do not contain an anthracycline.
IV The recommended IV dosage ratio of dexrazoxane:doxorubicin is 10:1 (eg, dexrazoxane 500 mg/m 2 would be given with doxorubicin 50 mg/m 2 ). In patients with moderate to severe renal function impairment (CrCl less than 40 mL/min), the recommended dosage ratio is 5:1. Doxorubicin must be administered within 30 min after starting the dexrazoxane infusion.ExtravasationAdults
IV Once daily for 3 consecutive days with the first dose administered as soon as possible and within 6 h after extravasation. Day 1: 1,000 mg/m 2 (max, 2,000 mg). Day 2: 1,000 mg/m 2 (max, 2,000 mg). Day 3: 500 mg/m 2 (max, 1,000 mg). Reduce the dose by 50% in patients with CrCl less than 40 mL/min.
Store powder for injection at controlled room temperature (59° to 86°F). Reconstituted and diluted solutions are stable for 6 h at controlled room temperature or under refrigeration (36° to 46°F). Discard any unused solution.Totect
Store unreconstituted vials at 59° to 86°F. Protect vials from light. Reconstituted product should be used immediately after mixing. The reconstituted product may be stored below 77°F for 4 h after mixing and diluting.
Dexrazoxane may interfere with the antitumor efficacy of this regimen. Coadministration is not recommended.Dimethylsulfoxide
Do not use with dexrazoxane to treat anthracycline-induced extravasation.Other chemotherapeutic agents
May increase the myelosuppressive effects of other chemotherapeutic agents.
Do not mix with other drugs.
None well documented.
Adverse reaction percentages reflect the use of dexrazoxane for the treatment of extravasation. The frequency of adverse reactions when dexrazoxane is used for the treatment of breast cancer is likely to be attributable to coadministration of doxorubicin or another concurrent regimen.
Vascular disorder (15%).
Pyrexia (21%); fatigue (13%); dizziness (11%); depression (8%); headache (6%); insomnia (5%); neurotoxicity.
Alopecia (14%); recall skin reaction, streaking/erythema; urticaria.
Nausea (43%); vomiting (19%); diarrhea (11%); abdominal pain, constipation (6%); anorexia (5%); dysphagia, esophagitis, stomatitis.
Anemia (6%); neutropenia, thrombocytopenia.
Decreased WBC (73%); decreased neutrophils (61%); decreased hemoglobin (43%); increased AST (28%); decreased platelets (26%); increased ALT (22%); increased creatinine (14%); increased bilirubin (11%); increased total calcium (7%); decreased sodium (6%); increased LDH (5%), increased alkaline phosphatase (4%).
Injection-site pain (16%); phlebitis (6%); extravasation.
Musculoskeletal and connective tissue disorders (13%).
Dyspnea (8%); pneumonia (6%); cough (5%).
Postoperative infection (16%); peripheral edema (10%); fever, hemorrhage, sepsis.
Ensure that CBC with differential is evaluated before starting therapy and frequently during treatment. Monitor patient for signs or symptoms of infection or bleeding.
Category C .Totect
Category D .
Safety and efficacy not established.
Cl is reduced in patients with renal function impairment. Dosage adjustments may be necessary.
Dose reduction is recommended.
Secondary malignancies (primarily acute myeloid leukemia) have been reported in patients treated chronically with razoxane.
Testicular atrophy in animals.
Carefully monitor cardiac function.
The use of dexrazoxane concurrently with the initiation of fluorouracil, doxorubicin, cyclosporine (FAC) therapy may interfere with the antitumor efficacy of the regimen; this use is not recommended.
Local irritation or phlebitis may occur. Refer to institution-specific protocol.
No data on overdosage.
Copyright © 2009 Wolters Kluwer Health.